Takeda and moderna announce plans to transfer marketing authorization for spikevax™ covid-19 vaccine in japan to moderna

Cambridge, mass. & osaka, japan--(business wire)--moderna, inc., (nasdaq: mrna) a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, and takeda (tse:4502/nyse:tak) announced to transfer the marketing authorization in japan for moderna's covid-19 vaccine spikevax™ (mrna-1273) from takeda to moderna in japan as of august 1, 2022. moderna will assume responsibility for all spikevax™ activities, including import, local regulatory, development, quality assurance and com
MRNA Ratings Summary
MRNA Quant Ranking